Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484861 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4815560 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL3545668 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL8483813 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL11050599 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4951882 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4954181 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL890725 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL483847 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4193998 | 0.93 | RECQL (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | claimed |
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-4232023-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| WO-2022238737-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | WO | disclosed |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4058065-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2022-09-21 | — | — | EP | disclosed |
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140155408-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2579377-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071733-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20120172349-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | SCHRODINGER, LLC. | 2012-07-05 | — | — | US | disclosed |
| US-20120029223-A1 | METHOD FOR PRODUCTION OF SUBSTITUTED ALKYL MALONIC ESTERS AND DERIVATIVES THEREOF | APOSENSE LTD. (IL) | 2012-02-02 | — | — | US | disclosed |
| US-7411096-B2 | Process for producing optically active phosphorus heterocyclic dimer | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20060211888-A1 | 2,2'-bis-(1-alkylphosphetanes); a primary alkyl or cycloalkyl phosphine is reacted with 1,3-dichloropropane, in the presence of n-butyllithium, and then reacted with boron trihydride, oxygen, or sulfur, dimerizing, removing the boron trihydride, oxygen, or sulfur; assymetric hydrogenation catalysts | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1650216-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE DIMER OF PHOSPHORUS HETEROCYCLE | NIPPON CHEMICAL INDUSTRIAL COMPANY LIMITED (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172349-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885CYP3A4 2291/4885CYP2C9 3911/4885 |
| US-20060211888-A1 | 2,2'-bis-(1-alkylphosphetanes); a primary alkyl or cycloalkyl phosphine is reacted with 1,3-dichloropropane, in the presence of n-butyllithium, and then reacted with boron trihydride, oxygen, or sulfur, dimerizing, removing the boron trihydride, oxygen, or sulfur; assymetric hydrogenation catalysts | OSBP2, OXSR1, OCIAD2 | ALDH1A1 3674/4885CYP3A4 3353/4885CYP2C9 3111/4885 |
| US-20120029223-A1 | METHOD FOR PRODUCTION OF SUBSTITUTED ALKYL MALONIC ESTERS AND DERIVATIVES THEREOF | ME1, MAL2, ME3 | ALDH1A1 691/4885CYP3A4 528/4885CYP2C9 887/4885 |
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | ALDH1A1 2065/4885CYP3A4 4390/4885CYP2C9 4693/4885 |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | TTK, MKNK1, MAP3K20 | ALDH1A1 4158/4885CYP3A4 4456/4885CYP2C9 4632/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | ALDH1A1 1759/4885CYP3A4 678/4885CYP2C9 1350/4885 |
| US-20140155408-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | ALDH1A1 1517/4885CYP3A4 1787/4885CYP2C9 3993/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | ALDH1A1 1759/4885CYP3A4 678/4885CYP2C9 1350/4885 |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | ALDH1A1 1847/4885CYP3A4 702/4885CYP2C9 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.